<DOC>
	<DOCNO>NCT01421147</DOCNO>
	<brief_summary>The purpose study compare effectiveness safety LY2963016 versus Lantus take daily combination insulin lispro meal three time day .</brief_summary>
	<brief_title>A Study Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have type 1 diabetes mellitus base disease diagnostic criterion [ World Health Organization ( WHO ) Classification ] Have duration diabetes great equal one year Have Hemoglobin A1c ( HbA1c ) less equal 11.0 % On basalbolus insulin therapy least 1 year [ basal insulin must daily ( QD ) injection human insulin isophane suspension ( NPH ) , Lantus , detemir combine mealtime injection human regular insulin , insulin analog lispro , aspart glulisine ] Have body mass index ( BMI ) less equal 35 kilograms/square meter ( kg/mÂ² ) Have one episode severe low blood sugar ( define need someone else help low blood sugar ) within 6 month enter study Have one episode diabetic ketoacidosis emergency room visit uncontrolled diabetes lead hospitalization within 6 month enter study Have know hypersensitivity allergy study insulin ( insulin glargine insulin lispro ) excipients study insulin Have significant renal , cardiac , gastrointestinal liver disease Have active cancer cancer within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>